Hollmén, Maria
Laaka, Atte
Partanen, Juulia J.
Koskela, Jukka
Sutinen, Eva
Kaarteenaho, Riitta
Ainola, Mari
Myllärniemi, Marjukka
Funding for this research was provided by:
Academy of Finland
Hengityssairauksien Tutkimussäätiö
Tampereen Tuberkuloosisäätiö
Nummela sanatorium
Helsinki University Hospital Funds
The Finnish TB foundation
Boehringer Ingelheim Fonds
University of Helsinki including Helsinki University Central Hospital
Article History
Received: 13 June 2023
Accepted: 15 September 2023
First Online: 30 September 2023
Declarations
:
: This study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) (HUS/2550/2017) and a research permit (HUS/8/2022). All participants provided written informed consent to participate in the Finnish IPF study and separate consent and blood samples from any of the Finnish biobanks.
: Not applicable.
: RK reports grants for the clinical group from the Tampere Tuberculosis Foundation, the Jalmari and Rauha Ahokas Foundation, the Research Foundation of the Pulmonary Diseases, the Finnish Anti-Tuberculosis Association Foundation, and the State subsidy of Oulu University Hospital; honoraria for lectures, consultancies, and virtual congress fees from Boehringer-Ingelheim, MSD, Novartis, and Roche; and leadership or fiduciary role as a President of the Finnish Respiratory Society (2017–2020), a member of the board of the Finnish Medical Foundation (1/2020–12/2022), and a member of the board of the Finnish Lung Health Association (1/2021–onwards). MH reports honoraria for lectures from Boehringer-Ingelheim, MSD, and AstraZeneca; participation on an advisory board for Boehringer-Ingelheim; travel support from MSD; and owns stock in Eli Lilly. Reported interests are all outside the submitted work. All other authors declare no competing interests.